$45.37
-0.03 (-0.07%)
Open$46.12
Previous Close$45.40
Day High$46.87
Day Low$45.11
52W High$47.84
52W Low$7.40
Volume—
Avg Volume575.8K
Market Cap2.84B
P/E Ratio—
EPS$-4.17
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
-71.8% upside
Current
$45.37
$45.37
Target
$12.80
$12.80
$8.80
$12.80 avg
$18.52
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 639.02M | 671.15M | 526.83M |
| Net Income | 3.07M | 3.06M | 2.31M |
| Profit Margin | 0.5% | 0.5% | 0.4% |
| EBITDA | 3.98M | 4.67M | 3.27M |
| Free Cash Flow | 2.86M | 3.84M | 2.49M |
| Rev Growth | +2.1% | +18.5% | -6.0% |
| Debt/Equity | 0.55 | 0.45 | 0.49 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |